الفهرس 
Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 194 |  |  |
| | | from | 194 | | |
Abstract
Hematopoietic stem-cell transplantation (HSCT) offers a unique opportunity for long-term disease control to many patients with severe malignant or non-malignant, acquired or congenital disorders of the hematopoietic system, or with chemo-sensitive, radiosensitive or immuno-sensitive tumors. Stem cells from peripheral blood, bone marrow or cord blood are used as the graft product. HSCT has seen rapid expansion over recent decades. It is considered the treatment of choice in several circumstances, and it is integrated into the treatment algorithm for many disease categories from diagnosis. Although advances in immunosuppressive therapy and management of infections have improved long-term survival, transplant recipients remain at risk for a multitude of complications, many of which are serious and life threatening. Post-transplant complications may be classified either according to the organ system or according to the timeframe following transplantation. Complications may involve the chest, abdomino-pelvic organs, the central nervous system, or musculoskeletal tissues. Comorbidity, as defined by Feinstein is any distinct additional clinical entity that has existed or may occur during the clinical course of a patient with a primary (index) disease. Comorbidities affect therapeutic plans and post-therapeutic outcomes of the index disease. In patients with cancer as the index disease, multiple studies have demonstrated the relevance of comorbidities in the prognosis. The number of comorbidities was suggested to increase with aging of cancer patients. With the advent of minimally toxic conditioning regimens, the hematopoietic cell transplantation (HCT) choices have been expanded to include older patients and those with comorbidities such as HIV infection. Therefore, it became critical to begin learning about the impacts of multiple comorbidities on outcomes after allogeneic HCT. The advent of the Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) allowed for more accurate evaluation of the burden of comorbidities at the time of HCT. Further, the HCT-CI proved to be a sensitive tool in predicting outcomes among patients diagnosed with lymphogenous or myelogenous malignancies and given allogeneic or autologous HCT. It provides additional prognostic information to performance status scales and could be used to correct for comparisons or trial outcomes